Beximco Pharma appoints Pr Mamtaz Uddin Ahmed to its Board as Independent Director

– BANGLADESH, Dhaka –  Beximco Pharmaceuticals Limited (LON: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announced the appointment of Professor Mamtaz Uddin Ahmed to its Board as an Independent Non-Executive Director effective immediately.

“I am delighted that Professor Ahmed has agreed to join the Board. He brings an impressive level of boardroom experience and financial knowledge, which will be invaluable to the Company as we continue to implement our growth strategy across the domestic and international markets.” said Board Chairman, S F Rahman.

About Professor Ahmed

Professor Ahmed has over 35 years’ teaching experience in finance and he is currently Professor of the Department of Accounting and Information Systems, and Chairman of the Bureau of Business Research, at the University of Dhaka, Bangladesh. Professor Ahmed is also an experienced board member, currently holding senior positions in the medical device company, Sysmark Ltd., and the Bangladesh government-owned power company, Ashuganj Power Station Company Ltd. His previous board positions include Director of the Chittagong Stock Exchange Ltd. and Director of the Dhaka Stock Exchange Ltd. In addition, Professor Ahmed is the Vice President of the South Asian Federation of Accountants and the former President of the Institute of Cost and Management Accountants of Bangladesh.

About Beximco Pharmaceuticals

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company’s broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 5,500 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.

For more information :

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.